Covetrus (CVET) Misses Q4 EPS by 27c

Covetrus (NASDAQ: CVET) reported Q4 EPS of ($0.02), $0.27 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.14 billion.

2022 Financial Guidance

Covetrus’ full-year 2022 financial guidance is as follows:

• Organic net sales growth, a non-GAAP financial metric, of 7% to 8%.
• Adjusted EBITDA, a non-GAAP financial metric, of $270 million to $280 million.

For earnings history and earnings-related data on Covetrus (CVET) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49